Minyoung Kevin Kim

Minyoung Kevin Kim

Auto-generated profile, based on publicly available information

Minyoung Kevin Kim

Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University, Stanford, California, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 November 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
MKMinyoung Kevin Kim
Minyoung Kevin Kim
QCQingquan Chen
Qingquan Chen
AEArne Echterhof
Arne Echterhof
NPNina Pennetzdorfer
Nina Pennetzdorfer
RMRobert C. McBride
Robert C. McBride
PBPaul Bollyky
Paul Bollyky
Bacteriophage (phage) therapy is a promising therapeutic modality for multidrug-resistant bacterial infections, but its application is mainly limited to personalized therapy due to the narrow host range of individual phages. While phage cocktails targeting all possible bacterial receptors could theoretically confer broad coverage, the extensive diversity of bacteria and the complexity of phage-phage interactions render this approach challenging. Here, using screening protocols for identifying “complementarity groups” of phages using non-redundant receptors, we generate effective, broad-range phage cocktails that prevent the emergence of bacterial resistance. We also discover characteristic interactions between phage complementarity groups and particular antibiotic classes, facilitating the prediction of phage-antibiotic as well as phage-phage interactions. Using this strategy, we create three phage-antibiotic cocktails, each demonstrating efficacy against ≥96% of 153 Pseudomonas aeruginosa clinical isolates, including biofilm cultures, and demonstrate comparable efficacy in an in vivo wound infection model. We similarly develop effective Staphylococcus aureus phage-antibiotic cocktails and demonstrate their utility of combined cocktails against polymicrobial (mixed P. aeruginosa/S. aureus) cultures, highlighting the broad applicability of this approach. These studies establish a blueprint for the development of effective, broad-spectrum phage-antibiotic cocktails, paving the way for off-the-shelf phage-based therapeutics to combat multidrug-resistant bacterial infections.

31 December 2024 in Journal of Clinical Investigation
Verified
Journal Article
Open access
MKMinyoung Kevin Kim
Minyoung Kevin Kim
GSGina Suh
Gina Suh
GCGrace D. Cullen
Grace D. Cullen
SRSaumel Perez Rodriguez
Saumel Perez Rodriguez
TDTejas Dharmaraj
Tejas Dharmaraj
JSJessica Christiane Sacher
Jessica Christiane Sacher
Bacteriophage (phage) therapy has emerged as a promising solution to combat the growing crisis of multidrug-resistant (MDR) infections. There are several international centers actively engaged in implementation of phage therapy, and recent case series have reported encouraging success rates in patients receiving personalized, compassionate phage therapy for difficult-to-treat infections. Nonetheless, substantial hurdles remain in the way of more widespread adoption and more consistent success. This Review offers a comprehensive overview of current phage therapy technologies and therapeutic approaches. We first delineate the common steps in phage therapy development, from phage bank establishment to clinical administration, and examine the spectrum of therapeutic approaches, from personalized to fixed phage cocktails. Using the framework of a conventional drug development pipeline, we then identify critical knowledge gaps in areas such as cocktail design, formulation, pharmacology, and clinical trial design. We conclude that, while phage therapy holds promise, a structured drug development pipeline and sustained government support are crucial for widespread adoption of phage therapy for MDR infections.

22 August 2019 in Journal of Clinical Laboratory Analysis
Verified
Journal Article
Open access
PDF file
MKMinyoung Kevin Kim
Minyoung Kevin Kim
HCHyeok Choi
Hyeok Choi
JKJae Yeon Kim
Jae Yeon Kim
JSJason Jungsik Song
Jason Jungsik Song
YPYong-Beom Park
Yong-Beom Park
SLSang-Won Lee
Sang-Won Lee
Background: So far, there has been no tool to estimate activity at diagnosis and predict all‐cause mortality in patients with ANCA‐associated vasculitis (AAV). Hence, we determined the initial predictors of them in patients with AAV. Methods: We retrospectively reviewed the medical records of 182 patients with AAV. Severe AAV was defined as Birmingham Vasculitis Activity Score (BVAS) ≥ 16. The cutoffs were extrapolated by the receiver operator characteristic (ROC) curve. The odds ratio (OR) and the relative risk (RR) were assessed using the multivariable logistic regression analysis and the chi‐square test, respectively. Results: In the comparison analysis, patients with severe AAV exhibited the higher neutrophil and platelet counts, creatinine, erythrocyte sedimentation rate and C‐reactive protein, and the lower lymphocyte count, hemoglobin, and serum albumin than those without. In the multivariable logistic regression analysis, creatinine ≥ 0.9 mg/dL (OR 2.264), lymphocyte count ≤ 1430.0/mm 3 (OR 1.856), and hemoglobin ≤ 10.8 g/dL (OR 2.085) were associated with severe AAV. We developed a new equation of a multivariable index for AAV (MVIA) = 0.6 × (Lymphocyte count ≤ 1430.0/mm 3 ) + 0.7 × (Hemoglobin ≤ 10.8 g/dL) + 0.8 × (Creatinine ≥ 0.9 mg/dL). The optimal cutoff of MVIA for severe AAV was set as 1.35. Severe AAV was identified more frequently in patients with MVIA at diagnosis ≥1.35 than those without (RR 4.432). Patients with MVIA at diagnosis ≥1.35 exhibited the lower cumulative patient survival rate than those without. Conclusion: Multivariable index for AAV could assess the cross‐sectional activity and predict all‐cause mortality in patients with AAV.

1 January 2020 in Yonsei Medical Journal
Verified
Journal Article
Open access
PDF file
HKHyeok Chan Kwon
Hyeok Chan Kwon
MKMinyoung Kevin Kim
Minyoung Kevin Kim
JSJason Jungsik Song
Jason Jungsik Song
YPYong-Beom Park
Yong-Beom Park
SLSang-Won Lee
Sang-Won Lee
Kwon HC, et al. Yonsei Med J. 2020 Aug;61(8):712-719. https://doi.org/10.3349/ymj.2020.61.8.712

1 January 2021 in Yonsei Medical Journal
Verified
Journal Article
Open access
PDF file
MKMinyoung Kevin Kim
Minyoung Kevin Kim
HKHyeok Chan Kwon
Hyeok Chan Kwon
JSJason Jungsik Song
Jason Jungsik Song
YPYong-Beom Park
Yong-Beom Park
SLSang-Won Lee
Sang-Won Lee
Kim MK, et al. Yonsei Med J. 2021 Feb;62(2):149-158. https://doi.org/10.3349/ymj.2021.62.2.149

1 August 2019 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
JKJae Yeon Kim
Jae Yeon Kim
HCHyeok Choi
Hyeok Choi
MKMinyoung Kevin Kim
Minyoung Kevin Kim
SLSoo Bin Lee
Soo Bin Lee
YPYong-Beom Park
Yong-Beom Park
SLSang-Won Lee
Sang-Won Lee